January 2026
Mystical experience
What January 2026's 7 new studies found, synthesized from the papers below. All Mystical experience research →
The synthesis
Synthesized from 7 studies in the library · AI-generated, grounded in the abstracts below
Found by searching the library for Mystical experience, mystical-type experience, ego dissolution, unitive experience, peak experience, then ranked by relevance.
Research in January 2026 found that mystical experiences are strongly influenced by psychological context (set) and spirituality, with psilocybin-assisted therapy studies showing significant associations between spirituality, intentions, and mystical experience intensity. A real-world case series on ketamine combined with psychotherapy found that ego dissolution (a mystical-type experience) correlated with symptom improvement in treatment-resistant depression. However, evidence is limited by small sample sizes, open-label designs, and the theoretical nature of some studies.
Evidence by study
Direction is which way each study's own result points, not our rating of the study.
What the directions mean
- Supports:
- the study found the intervention worked, or its hypothesis held.
- Opposes:
- it found the opposite, no benefit or a harm.
- No effect:
- no significant difference either way.
- Mixed:
- effects in both directions within the same study.
- Unclear:
- the abstract does not report a direction.
| Study | Design | Sample size | Direction | Finding |
|---|---|---|---|---|
| Numinous-like symptoms in epilepsy and/or insular tumors: A hospital cohort study. 2026 | observational cohort | 106 | Supports | Numinous-like symptoms (including mystical features) were found in 6% of epilepsy patients and 8.7% of tumor patients, with identified ecstatic seizures, out-of-body experiences, and sensed presence. |
| Mindset over molecule: comparing self-transcendent and mystical experiences across recreational psilocybin, MDMA, and cannabis use 2026 | observational | Supports | Psychological context (set) was more strongly associated with self-transcendent and mystical experiences than the specific substance used, supporting a 'mindset-over-molecule' pattern. | |
| Intentions, Spirituality, Set, and Setting Are Associated with Mystical Experiences in Psilocybin-Assisted Therapy 2026 | open-label trial | 20 | Supports | Mystical experience intensity was significantly associated with spirituality (rs=0.76), spiritual intentions (rs=0.71), positive mindset (rs=0.52), and positive perceptions of setting (rs=0.46) in psilocybin-assisted therapy. |
| Psychedelics in the age of reproducibility: Reflections on aura, set and setting and the medicalization of mystical-type experiences. 2026 | theoretical | Unclear | The article uses Walter Benjamin's concept of 'aura' to discuss tensions between authenticity and standardization when psychedelic mystical experiences are medicalized. | |
| Ketamine combined with psychotherapy for treatment-resistant depression: Real-world outcomes and the role of subjective experience. 2026 | case series | 12 | Supports | Ego dissolution during ketamine session 3 correlated with symptom improvement and psychological insight; 67% response and 58% remission rates were observed, with 50% maintaining remission at 1-year follow-up. |
| Realization experiences: a convergent account of insight and mystical experiences 2026 | theoretical | Unclear | The article proposes that mystical experiences and insight are both 'realization experiences' that can be modeled using behavioral entropy and graph theory. | |
| Understanding Relationship between Mystical Experiences and Yoga-based Personality Traits in Meditators, Patients with Psychosis, and Psychedelic Users: A Cross-sectional Study 2026 | cross-sectional | 55 | Supports | The study examined relationships between mystical experiences and yoga-based personality traits (Kleshas, Gunas, yogic modes of consciousness) in those who had mystical experiences on psychedelics or otherwise. |
Numinous-like symptoms (including mystical features) were found in 6% of epilepsy patients and 8.7% of tumor patients, with identified ecstatic seizures, out-of-body experiences, and sensed presence.
observational cohort Sample size: 106
Psychological context (set) was more strongly associated with self-transcendent and mystical experiences than the specific substance used, supporting a 'mindset-over-molecule' pattern.
observational
Mystical experience intensity was significantly associated with spirituality (rs=0.76), spiritual intentions (rs=0.71), positive mindset (rs=0.52), and positive perceptions of setting (rs=0.46) in psilocybin-assisted therapy.
open-label trial Sample size: 20
The article uses Walter Benjamin's concept of 'aura' to discuss tensions between authenticity and standardization when psychedelic mystical experiences are medicalized.
theoretical
Ego dissolution during ketamine session 3 correlated with symptom improvement and psychological insight; 67% response and 58% remission rates were observed, with 50% maintaining remission at 1-year follow-up.
case series Sample size: 12
The article proposes that mystical experiences and insight are both 'realization experiences' that can be modeled using behavioral entropy and graph theory.
theoretical
The study examined relationships between mystical experiences and yoga-based personality traits (Kleshas, Gunas, yogic modes of consciousness) in those who had mystical experiences on psychedelics or otherwise.
cross-sectional Sample size: 55
Points of agreement
- Mystical experiences are strongly influenced by psychological context (set) and spirituality.
- Mystical-type experiences (including ego dissolution) may correlate with therapeutic outcomes in psychedelic and ketamine treatments.
- The importance of set and setting is consistently emphasized across empirical and theoretical studies.
Conflicts
- No direct conflicts were identified among the studies; however, the evidence base is too small and heterogeneous to assess consistency across different substances and populations.
Gaps
- Durability of mystical experience effects beyond short-term follow-up is not well studied.
- Blinding and placebo controls are lacking in most studies.
- Sample sizes are very small (n=12 to n=55 completers), limiting generalizability.
- Diverse populations (epilepsy, AUD, TRD, recreational users) make cross-study comparisons difficult.
- The role of dose, specific substances, and long-term safety remains understudied.